Why Stopping GLP-1 Drugs Could Lead to Unexpected Health Risks

While GLP-1 medications like Ozempic, Wegovy and Zepbound have reshaped weight management and diabetes control, research shows that many patients stop taking them within a year.

Research has found that cycling off these medications can bring potential rebound risks, ranging from rapid weight regain to the loss of cardiovascular protection.

Dr. Frank Dumont, internal medicine physician and executive medical director at Virta Health in San Francisco, spoke with Fox News Digital about why patients stop taking GLP-1s, the potential risks and how to maintain progress afterward.